Catalyst Pharmaceuticals’ (CPRX) “Buy” Rating Reaffirmed at HC Wainwright

Catalyst Pharmaceuticals (NASDAQ:CPRX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $35.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 52.91% from the company’s current price.

Other analysts have also issued reports about the stock. Stephens reaffirmed an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. StockNews.com lowered shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Robert W. Baird initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 price target for the company. Finally, Bank of America reissued a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Trading Up 5.7 %

CPRX stock opened at $22.89 on Friday. Catalyst Pharmaceuticals has a one year low of $14.47 and a one year high of $24.64. The firm has a market capitalization of $2.73 billion, a PE ratio of 19.40, a P/E/G ratio of 3.31 and a beta of 0.80. The firm has a 50-day moving average of $22.24 and a two-hundred day moving average of $21.43.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the transaction, the insider now owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $27,000. Park Square Financial Group LLC bought a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $29,000. Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 1,495 shares in the last quarter. Larson Financial Group LLC raised its position in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $65,000. Institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.